Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999298 | 0.78 | KDM4E (0.40) | MEN1KMT2AKDM4EALOX15MAPK1 | |
| SCHEMBL2382965 | 0.68 | S1PR1 (0.41) | S1PR1S1PR3 | |
| SCHEMBL18529402 | 0.64 | HSD11B1 (0.35) | MEN1KMT2AHSD11B1 | |
| SCHEMBL11330952 | 0.61 | — | — | |
| SCHEMBL10445651 | 0.59 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL8768659 | 0.58 | KDM4E (0.35) | MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL4629067 | 0.57 | GAA (0.39) | KDM4EHSD17B10 | |
| SCHEMBL18999319 | 0.55 | KDM4E (0.43) | KDM4EALOX15MAPK1CASP1HSD17B10 | |
| SCHEMBL10111171 | 0.54 | — | — | |
| SCHEMBL2170979 | 0.53 | KDM4E (0.33) | KDM4EMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022225-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090131438-A1 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131438-A1 | Triazole derivative | S1PR3, S1PR1, S1PR2 | MEN1 1052/4885KMT2A 2948/4885KDM4E 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.